SCHEDULE: T. Rowe Price Reports Stake in Kodiak Sciences

T. Rowe Price Associates, Inc. has updated its beneficial ownership filing for Kodiak Sciences Inc., reporting a 5.2% stake as of June 30, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating a change in its beneficial ownership of Kodiak Sciences Inc. common stock.
• As of June 30, 2026, T. Rowe Price Associates, Inc. beneficially owns 3,248,611 shares, representing 5.2% of the class of securities.
• The filing specifies sole voting power for 3,247,060 shares and sole dispositive power for 3,248,611 shares.
• This filing is made under Rule 13d-1(b) and T. Rowe Price Associates, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage without new strategic information or financial performance data.

Positives

• T. Rowe Price Associates, Inc. maintains a significant stake, suggesting continued institutional interest in Kodiak Sciences Inc.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Kodiak Sciences Inc., making it difficult to assess the company's current operational health.
• The filing is a routine disclosure of beneficial ownership, not an indicator of new investment thesis or positive development.

Risks

• The filing itself does not introduce new risks, but the underlying business risks of Kodiak Sciences Inc. remain relevant to investors.
• Potential for future changes in beneficial ownership by T. Rowe Price Associates, Inc. could impact share price.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Kodiak Sciences Inc.'s future performance.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like T. Rowe Price Associates, Inc. when their beneficial ownership crosses certain thresholds. This filing indicates T. Rowe Price Associates, Inc. is a significant institutional holder in the biotechnology or pharmaceutical sector, where Kodiak Sciences Inc. operates.

Stakeholder Impact

• Shareholders: The filing confirms T. Rowe Price Associates, Inc. as a significant institutional investor, which can be viewed positively for stock stability and liquidity.
• Management of Kodiak Sciences Inc.: The filing is a standard disclosure and does not directly impact management's operational decisions, but signals institutional oversight.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold or trade its position in Kodiak Sciences Inc. according to its investment strategy.
• Kodiak Sciences Inc. will continue its business operations and disclosures.

Key Dates

Keywords

Kodiak Sciences, T. Rowe Price, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management